Key Provisions

Bulk Drug Substance must meet the USP (United States Pharmacopeia) or the applicable monograph, and must be either a component of an FDA‑approved drug or listed on the FDA 503A bulks list. This policy ensures that compounding firms use only safe, quality‑guaranteed raw materials.

Why Are the Regulations Strengthened Now?

Recent adverse events linked to unauthorized mixed drugs have prompted federal authorities to clarify standards as part of risk management. In particular, supply‑chain instability following the COVID‑19 pandemic increased the risk of illegal bulk drug substance use. Consequently, the FDA has re‑examined Section 503A and issued clear guidance.

Implications for Industry and Patients

Compounding pharmacies will now face additional administrative steps and verification when selecting raw materials, potentially raising operating costs. However, patients are more likely to receive drugs made from validated ingredients, substantially improving safety.

Differentiation from Competitors and Precedents

Previously, some companies applied internal verification criteria, but the new rule permits only substances identified in USP and on the FDA list. This enhances transparency relative to prior practice and enables objective assessment of regulatory compliance, markedly reducing violation risk.

Future Scenarios

If the regulation becomes entrenched, bulk drug substance suppliers will expand USP‑certified product lines, and compounding pharmacies will invest in certified supply‑chain infrastructure. Conversely, if the regulation is relaxed, quality‑control risks could re‑emerge.